Literature DB >> 11782540

A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Assaf Friedler1, Lars O Hansson, Dmitry B Veprintsev, Stefan M V Freund, Thomas M Rippin, Penka V Nikolova, Mark R Proctor, Stefan Rüdiger, Alan R Fersht.   

Abstract

Conformationally compromised oncogenic mutants of the tumor suppressor protein p53 can, in principle, be rescued by small molecules that bind the native, but not the denatured state. We describe a strategy for the rational search for such molecules. A nine-residue peptide, CDB3, which was derived from a p53 binding protein, binds to p53 core domain and stabilizes it in vitro. NMR studies showed that CDB3 bound to p53 at the edge of the DNA binding site, partly overlapping it. The fluorescein-labeled peptide, FL-CDB3, binds wild-type p53 core domain with a dissociation constant of 0.5 microM, and raises the apparent melting temperatures of wild-type and a representative oncogenic mutant, R249S core domain. gadd45 DNA competes with CDB3 and displaces it from its binding site. But this competition does not preclude CDB3 from being a lead compound. CDB3 may act as a "chaperone" that maintains existing or newly synthesized destabilized p53 mutants in a native conformation and then allows transfer to specific DNA, which binds more tightly. Indeed, CDB3 restored specific DNA binding activity to a highly destabilized mutant I195T to close to that of wild-type level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782540      PMCID: PMC117409          DOI: 10.1073/pnas.241629998

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Pharmacological rescue of mutant p53 conformation and function.

Authors:  B A Foster; H A Coffey; M J Morin; F Rastinejad
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

2.  ASPP proteins specifically stimulate the apoptotic function of p53.

Authors:  Y Samuels-Lev; D J O'Connor; D Bergamaschi; G Trigiante; J K Hsieh; S Zhong; I Campargue; L Naumovski; T Crook; X Lu
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

3.  Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases.

Authors:  I Takenaka; F Morin; B R Seizinger; N Kley
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

Review 4.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

5.  Small peptides activate the latent sequence-specific DNA binding function of p53.

Authors:  T R Hupp; A Sparks; D P Lane
Journal:  Cell       Date:  1995-10-20       Impact factor: 41.582

6.  The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity.

Authors:  J H Bayle; B Elenbaas; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

7.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.

Authors:  A N Bullock; J Henckel; A R Fersht
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

Review 8.  Strategies for manipulating the p53 pathway in the treatment of human cancer.

Authors:  T R Hupp; D P Lane; K L Ball
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

9.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

10.  Two cellular proteins that bind to wild-type but not mutant p53.

Authors:  K Iwabuchi; P L Bartel; B Li; R Marraccino; S Fields
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

View more
  66 in total

1.  Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor.

Authors:  Maria Rosario Fernandez-Fernandez; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

2.  CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.

Authors:  Xingxing He; Xinjuan Kong; Junwei Yan; Jingjun Yan; Yunan Zhang; Qian Wu; Ying Chang; Haitao Shang; Qian Dou; Yuhu Song; Fang Liu
Journal:  Tumour Biol       Date:  2015-02-08

3.  Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.

Authors:  Joel L Kaar; Nicolas Basse; Andreas C Joerger; Elaine Stephens; Trevor J Rutherford; Alan R Fersht
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

4.  Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.

Authors:  Zvi Hayouka; Joseph Rosenbluh; Aviad Levin; Shoshana Loya; Mario Lebendiker; Dmitry Veprintsev; Moshe Kotler; Amnon Hizi; Abraham Loyter; Assaf Friedler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

5.  Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2.

Authors:  Chen Katz; Hadar Benyamini; Shahar Rotem; Mario Lebendiker; Tsafi Danieli; Anat Iosub; Hadar Refaely; Monica Dines; Vered Bronner; Tsafrir Bravman; Deborah E Shalev; Stefan Rüdiger; Assaf Friedler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

6.  Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.

Authors:  Rainer Wilcken; GuoZhen Wang; Frank M Boeckler; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

7.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Authors:  Natalia Issaeva; Assaf Friedler; Przemyslaw Bozko; Klas G Wiman; Alan R Fersht; Galina Selivanova
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

8.  Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53.

Authors:  Lars O Hansson; Assaf Friedler; Stefan Freund; Stefan Rudiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

9.  A peptidomimetic approach to targeting pre-amyloidogenic states in type II diabetes.

Authors:  James A Hebda; Ishu Saraogi; Mazin Magzoub; Andrew D Hamilton; Andrew D Miranker
Journal:  Chem Biol       Date:  2009-09-25

10.  p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.

Authors:  Anuj Kumar Sharma; Amjad Ali; Rajan Gogna; Amir Kumar Singh; Uttam Pati
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.